✦ LIBER ✦

Erratum to: Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial

✍ Scribed by Ryuji Kaji; Yuka Osako; Kazuaki Suyama; Toshio Maeda; Yasuyuki Uechi; Masaru Iwasaki

Publisher: Springer
Year: 2010
Tongue: English
Weight: 86 KB
Volume: 257
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-010-5607-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Botulinum toxin type A in post-stroke lo

Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial

✍ Ryuji Kaji; Yuka Osako; Kazuaki Suyama; Toshio Maeda; Yasuyuki Uechi; Masaru Iwa 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 255 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor

✍ Dr. J. Jankovic; K. Schwartz; W. Clemence; A. Aswad; J. Mordaunt 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 585 KB

## Abstract Twenty‐five patients with hand tremor of 2 + (moderate) to 4 + (severe) on the tremor severity rating scale were randomized to receive either 50 U of botulinum toxin (BTX) type A (Allergan, Irvine, CA) or placebo injections into the wrist flexors and extensors of the dominant limb. If p

Botulinum toxin type-A in the prophylact

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study

✍ Giorgio Sandrini; Armando Perrotta; Cristina Tassorelli; Paola Torelli; Filippo 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 277 KB

Double-blind, placebo-controlled study t

Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism

✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini